Published in Medical Letter on the CDC and FDA, June 5th, 2005
During this period, the company recorded $5.5 million in product shipments of the company's lead product, FACTIVE (gemifloxacin mesylate) tablets, U.S. Food and Drug Administration (FDA)-approved for the treatment of acute bacterial exacerbations of chronic bronchitis (AECB) and mild to moderate community-acquired pneumonia (CAP).
Net of the impact from introductory promotional programs, the company recorded $3.9 million in product revenue for the first quarter of 2005. First quarter product revenues include the recognition of $390,000...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA